Volume 8 | Issue - 8
Volume 8 | Issue - 8
Volume 8 | Issue - 8
Volume 8 | Issue - 7
Volume 8 | Issue - 7
Background: Data on outcomes of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV)-related extrahepatic manifestations (EHMs) is scarce. We aimed to assess the safety and efficacy of sofosbuvir (SOF)-based regimens in HCVrelated EHMs.